Merkel Cell Carcinoma News and Research

RSS
Researchers identify oncoprotein that allows MCV virus to trigger Merkel Cell Carcinoma

Researchers identify oncoprotein that allows MCV virus to trigger Merkel Cell Carcinoma

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

OncoSec Medical third quarter net loss increases to $491,000

OncoSec Medical third quarter net loss increases to $491,000

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

Researchers take first step towards understanding of rare skin cancer

Researchers take first step towards understanding of rare skin cancer

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen first quarter net loss increases to $12.9 million

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

Immunogen reports a net loss of $12.1 million in third quarter 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

Researchers discover that Merkel cells originate in the skin

Researchers discover that Merkel cells originate in the skin

Researchers identify embryonic origin of Merkel cells

Researchers identify embryonic origin of Merkel cells